Literature DB >> 16630021

Interferon-alphabeta mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette-Guérin infection.

John Kuchtey1, Scott A Fulton, Scott M Reba, Clifford V Harding, W Henry Boom.   

Abstract

The role of type I interferon (IFN-alphabeta) in modulating innate or adaptive immune responses against mycobacterial infection in the lung is unclear. In this study we investigated the susceptibility of IFN-alphabeta-receptor-deficient (IFN-alphabetaR-/-) mice to pulmonary infection with aerosolized Mycobacterium bovis bacillus Calmette-Guérin (BCG). During early infection (2-3 weeks), enhanced growth of BCG was measured in the lungs of IFN-alphabetaR-/- mice compared to wild-type mice. However, during late infection the burden of BCG was similar in the lungs of IFN-alphabetaR-/- and wild-type mice. Although control of BCG growth was delayed, recruitment and activation of T and natural killer cells, production of IFN-gamma, and cytokine expression were all similar in wild-type and IFN-alphabetaR-/- mice. However, decreased expression of nitric oxide in bronchoalveolar lavage fluids from IFN-alphabetaR-/- mice correlated with enhanced growth of BCG. Bone marrow-derived macrophages from IFN-alphabetaR-/- mice also produced less nitric oxide following infection with BCG in vitro. These findings suggest that IFN-alphabeta contributes to innate immunity to pulmonary mycobacterial infection by augmenting production of nitric oxide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630021      PMCID: PMC1782276          DOI: 10.1111/j.1365-2567.2006.02337.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  49 in total

Review 1.  The function of type I interferons in antimicrobial immunity.

Authors:  C Bogdan
Journal:  Curr Opin Immunol       Date:  2000-08       Impact factor: 7.486

Review 2.  Interferons alpha and beta as immune regulators--a new look.

Authors:  C A Biron
Journal:  Immunity       Date:  2001-06       Impact factor: 31.745

3.  Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis.

Authors:  S Giosuè; M Casarini; F Ameglio; P Zangrilli; M Palla; A M Altieri; A Bisetti
Journal:  Eur Cytokine Netw       Date:  2000-03       Impact factor: 2.737

4.  Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains.

Authors:  A Takaoka; Y Mitani; H Suemori; M Sato; T Yokochi; S Noguchi; N Tanaka; T Taniguchi
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

5.  Mycobacterium tuberculosis inhibits MHC class II antigen processing in murine bone marrow macrophages.

Authors:  E H Noss; C V Harding; W H Boom
Journal:  Cell Immunol       Date:  2000-04-10       Impact factor: 4.868

6.  Role of type I interferons during macrophage activation by lipopolysaccharide.

Authors:  P K Vadiveloo; G Vairo; P Hertzog; I Kola; J A Hamilton
Journal:  Cytokine       Date:  2000-11       Impact factor: 3.861

7.  Lethal Mycobacterium bovis Bacillus Calmette Guérin infection in nitric oxide synthase 2-deficient mice: cell-mediated immunity requires nitric oxide synthase 2.

Authors:  I Garcia; R Guler; D Vesin; M L Olleros; P Vassalli; Y Chvatchko; M Jacobs; B Ryffel
Journal:  Lab Invest       Date:  2000-09       Impact factor: 5.662

8.  Regulation of type 2 nitric oxide synthase by type 1 interferons in macrophages infected with Leishmania major.

Authors:  J Mattner; H Schindler; A Diefenbach; M Röllinghoff; I Gresser; C Bogdan
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

9.  Pulmonary immune responses during primary mycobacterium bovis- Calmette-Guerin bacillus infection in C57Bl/6 mice.

Authors:  S A Fulton; T D Martin; R W Redline; W Henry Boom
Journal:  Am J Respir Cell Mol Biol       Date:  2000-03       Impact factor: 6.914

10.  Distinct requirements for IFNs and STAT1 in NK cell function.

Authors:  C K Lee; D T Rao; R Gertner; R Gimeno; A B Frey; D E Levy
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

View more
  20 in total

1.  cGAS-STING-TBK1-IRF3/7 induced interferon-β contributes to the clearing of non tuberculous mycobacterial infection in mice.

Authors:  Nanthapon Ruangkiattikul; Andreas Nerlich; Ketema Abdissa; Stefan Lienenklaus; Abdulhadi Suwandi; Nina Janze; Kristin Laarmann; Julia Spanier; Ulrich Kalinke; Siegfried Weiss; Ralph Goethe
Journal:  Virulence       Date:  2017-04-19       Impact factor: 5.882

2.  Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency.

Authors:  Carla M Ward; Harumi Jyonouchi; Sergei V Kotenko; Sergey V Smirnov; Rakesh Patel; Helen Aguila; George McSherry; Barry Dashefsky; Steven M Holland
Journal:  Eur J Pediatr       Date:  2006-11-21       Impact factor: 3.183

3.  Modulation of naive CD4+ T-cell responses to an airway antigen during pulmonary mycobacterial infection.

Authors:  Mursalin M Anis; Scott A Fulton; Scott M Reba; Clifford V Harding; W Henry Boom
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

4.  Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model. A role for type I interferon.

Authors:  Amber Troy; Sandra C Esparza-Gonzalez; Alicia Bartek; Elizabeth Creissen; Linda Izzo; Angelo A Izzo
Journal:  Tuberculosis (Edinb)       Date:  2020-06-06       Impact factor: 3.131

5.  Mycobacterium bovis BCG decreases MHC-II expression in vivo on murine lung macrophages and dendritic cells during aerosol infection.

Authors:  Nicole D Pecora; Scott A Fulton; Scott M Reba; Michael G Drage; Daimon P Simmons; Nancy J Urankar-Nagy; W Henry Boom; Clifford V Harding
Journal:  Cell Immunol       Date:  2008-08-30       Impact factor: 4.868

6.  Modulation of pulmonary dendritic cell function during mycobacterial infection.

Authors:  Mursalin M Anis; Scott A Fulton; Scott M Reba; Yi Liu; Clifford V Harding; W Henry Boom
Journal:  Infect Immun       Date:  2007-11-26       Impact factor: 3.441

7.  Exacerbated type II interferon response drives hypervirulence and toxic shock by an emergent epidemic strain of Streptococcus suis.

Authors:  Claude Lachance; Marcelo Gottschalk; Pehuén P Gerber; Paul Lemire; Jianguo Xu; Mariela Segura
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441

8.  Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis.

Authors:  M I Gabrilovich; J Walrath; J van Lunteren; D Nethery; M Seifu; J A Kern; C V Harding; L Tuscano; H Lee; S D Williams; W Mackay; J F Tomashefski; R F Silver
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

9.  Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis.

Authors:  Ludovic Desvignes; Andrea J Wolf; Joel D Ernst
Journal:  J Immunol       Date:  2012-05-07       Impact factor: 5.422

10.  Interferon alpha treatment of patients with impaired interferon gamma signaling.

Authors:  H I Bax; A F Freeman; L Ding; A P Hsu; B Marciano; E Kristosturyan; T Jancel; C Spalding; J Pechacek; K N Olivier; L A Barnhart; L Boris; C Frein; R J Claypool; V Anderson; C S Zerbe; S M Holland; E P Sampaio
Journal:  J Clin Immunol       Date:  2013-03-20       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.